113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05160415 (ClinicalTrials.gov) | December 2021 | 2/12/2021 | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy | Becker Muscular Dystrophy | Drug: EDG-5506 | Edgewise Therapeutics, Inc. | Medpace, Inc. | Recruiting | 18 Years | 55 Years | Male | 8 | Phase 1 | United States |
| 2 | NCT04585464 (ClinicalTrials.gov) | October 12, 2020 | 2/10/2020 | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults | A Phase 1, Randomized, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and PK of EDG-5506 in Adult Healthy Volunteers and Adults With Becker Muscular Dystrophy | Healthy Volunteer;Becker Muscular Dystrophy | Drug: EDG-5506;Drug: Placebo | Edgewise Therapeutics, Inc. | Worldwide Clinical Trials | Completed | 18 Years | 55 Years | All | 128 | Phase 1 | United States |